Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19

Am J Med Sci. 2023 Feb;365(2):215-217. doi: 10.1016/j.amjms.2022.10.012. Epub 2022 Nov 3.

Authors

Gisela Garcia-Arellano¹, Adrian Camacho-Ortiz², Ilse Andrea Moreno-Arquieta¹, Jesus Alberto Cardenas-de la Garza¹, Diana Carolina Rubio-Torres¹, Elvira Garza-Gonzalez², Paola Bocanegra-Ibarias², Dionicio Angel Galarza-Delgado³

Affiliations

¹ Rheumatology Service, "Dr José Eleuterio González" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, México.
² Infectiology Department, "Dr José Eleuterio González" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, México.
³ Rheumatology Service, "Dr José Eleuterio González" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, México. Electronic address: dgalarza@medicinauanl.mx.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Anticardiolipin
Autoantibodies
COVID-19*
Enzyme-Linked Immunosorbent Assay
Glycoproteins
Humans

Substances

Autoantibodies
Glycoproteins
Antibodies, Anticardiolipin